FGFR2 and urothelial carcinoma: Erdafitinib should be considered for FGFR2/3 variant urothelial carcinoma treatment (FDA-approved for locally advanced or metastatic urothelial carcinoma after platinum-based chemotherapy, undergoing NMPA listing in China)